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Abstract
Context: Surfactant protein-D (SP-D) is a primordial component of the innate immune system intrinsically linked to
metabolic pathways. We aimed to study the association of single nucleotide polymorphisms (SNPs) affecting SP-D with
insulin resistance and type 2 diabetes (T2D).
Research Design and Methods: We evaluated a common genetic variant located in the SP-D coding region (rs721917,
Met31Thr) in a sample of T2D patients and non-diabetic controls (n = 2,711). In a subset of subjects (n = 1,062), this SNP was
analyzed in association with circulating SP-D concentrations, insulin resistance, and T2D. This SNP and others were also
screened in the publicly available Genome Wide Association (GWA) database of the Meta-Analyses of Glucose and Insulin-
related traits Consortium (MAGIC).
Results: We found the significant association of rs721917 with circulating SP-D, parameters of insulin resistance and T2D.
Indeed, G carriers showed decreased circulating SP-D (p = 0.004), decreased fasting glucose (p = 0.0002), glycated
hemoglobin (p = 0.0005), and 33% (p = 0.002) lower prevalence of T2D, estimated under a dominant model, especially
among women. Interestingly, these differences remained significant after controlling for origin, age, gender, and circulating
SP-D. Moreover, this SNP and others within the SP-D genomic region (i.e. rs10887344) were significantly associated with
quantitative measures of glucose homeostasis, insulin sensitivity, and T2D, according to GWAS datasets from MAGIC.
Conclusions: SP-D gene polymorphisms are associated with insulin resistance and T2D. These associations are independent
of circulating SP-D concentrations.
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Introduction
Over nutrition and sedentary activities, in combination with
repeated exposure to infectious agents and external injuries, could
compromise the homeostasis of the innate immune system, leading
to chronic subclinical inflammation, which is intrinsic to the
metabolic syndrome [1]. Insulin resistance seems to be central to
the pathophysiology of these alterations [2]. Approaches to this
hypothesis have been made through the study of acute phase and
innate immune proteins in association with insulin resistance and
type 2 diabetes (T2D) [3]. Bactericidal/permeability-increasing
protein, lipopolysaccharide binding protein, complement factors,
a-defensins, and lactoferrin are examples of proteins from the
innate immune system closely associated with metabolic param-
eters [4,5,6,7].
Surfactant protein-D (SP-D) is a key-factor of the innate
immunity system which develops its principal activity in lungs,
protecting from inhaled microorganisms, organic antigens, and
toxins [8]. SP-D modulates the leukocyte action contributing to
the inflammatory response [9], and interacts with compounds such
as bacterial lipopolysaccharides (LPS), oligosaccharides, and fatty
acids [10]. The SP-D single nucleotide polymorphism (SNP)
rs721917 (NC_000010.10: g.81706324A.G) is a missense substi-
tution which leads the replacement in position 31 of an ancestral
metionine by a threonine (Met31Thr) [10]. This polymorphic
variation in the N-terminal domain of the SP-D molecule
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influences oligomerization, function, and circulating concentra-
tions [11], leading to decreased immunologic capacity against
bacteria [10]. Indeed, subjects carrying AA-genotype (Met/Met)
have increased concentrations of SP-D in plasma [12], and show
multimers, dodecamers, and monomers of subunits, whereas GG-
carriers (Thr/Thr) produce almost exclusively monomers [11].
Previous evidence disclosed associations of low vital capacity
and low weight at birth with an increased risk of T2D [13]. The
close relationship between pulmonary acute phase proteins, the
inflammatory state, and the development of metabolic complica-
tions has been also demonstrated [14,15,16,17,18]. However, the
mechanisms of these interactions depend on scarcely known
factors. In a previous manuscript, we provided data according to
which low circulating SP-D concentrations were associated with
increased fat accumulation and decreased insulin sensitivity [19].
Given the relationships among SP-D, insulin resistance and T2D,
we hypothesized that genetic alteration in the former could be also
associated with the prevalence of insulin resistance and T2D.
Methods
Subject Recruitment
Data and samples from 2,711 Caucasian subjects were obtained
from population based prospective studies performed in three
regions of Spain between 1996 and 1999:680 subjects were
recruited from the North-West (Asturias) [20], 1,341 from the
center (Madrid) [21], and 690 from the North-East (Girona) [7].
Eligible participants were selected at random from the census and,
after a screening visit, they were invited to participate. The
participation rate was higher than 70%. The mean age of the
participants was 51+/212 years; 1,344 were men and 1,367 were
women. Baseline studies included a standardized questionnaire,
physical examination, and laboratory tests. Height and weight
were measured with the participant in light clothing and without
shoes by trained personnel using calibrated scales and a wall-
mounted stadiometer, respectively. BMI was calculated by
dividing weight in kilograms by the square of the height in
meters. Waist circumference was measured to the nearest 0.5 cm
midway between the lowest rib and the iliac crest using an
anthropometric tape. Blood pressure was measured in the supine
position on the right arm after a 10-min rest; a standard
sphygmomanometer of appropriate cuff size was used and the
first and fifth phases were recorded. Values used in the analysis are
the average of three readings taken at 5 min intervals. Fasting
serum and plasma was withdrawn and stored at 280uC until
analysis. According to the American Diabetes Association Criteria
a 75 g oral glucose tolerance test was performed in all subjects.
Type 2 diabetes (T2D) was diagnosed in subjects having fasting
plasma glucose .7 mM and two-hour post-load plasma glucose
.11.1 mM after the oral glucose tolerance test. T2D patients were
also prospectively recruited from outpatient clinics on the basis of a
stable metabolic control in the previous 6 months, as defined by
Figure 1. Genotypes for rs721917 and measures of impaired glucose tolerance and circulating SP-D. Mean and 95% confidence interval
for fasting glucose (Fig. 1a) and glycated hemoglobin (Fig. 1b) for the whole cohort (n = 2,711), and for circulating SP-D concentration (Fig. 1c),
fasting glucose (Fig. 1d) and glycated hemoglobin (Fig. 1d) in a subpopulation of subjects (n = 1,062) according to the genotypes for rs721917.
Men: black bars, women: grey bars. *p,0.05 and #p,0.0001 for comparisons with AA-genotype.
doi:10.1371/journal.pone.0060468.g001
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stable HbA1c values. Inclusion criteria were: 1) absence of
systemic and metabolic disease other than obesity and T2D, and
2) absence of infection within the previous month. Liver disease
and thyroid dysfunction were specifically excluded by biochemical
work-up. Other exclusion criteria included the following: 1)
clinically significant hepatic, neurological, endocrinologic, or other
major systemic disease, including malignancy; 2) history or current
clinical evidence of hemochromatosis; 3) history of drug or alcohol
abuse, defined as.80 g/day in men and.40 g/day in women; 4)
elevated serum creatinine concentration; 5) acute major cardio-
vascular event in the previous 6 months; 6) acute illnesses and
current evidence of acute or chronic inflammatory or infective
diseases; and 7) mental illness rendering the subjects unable to
understand the nature, scope, and possible consequences of the
study. All participants were requested to withhold alcohol and
caffeine during at least 12 h prior to the different tests. All subjects
gave written informed consent after the purpose of the study was
explained to them. The experimental protocol was approved by
the Ethics Committee of all participant institutions, including the
Hospital Central de Asturias (Asturias, Spain), the Hospital Clı´nico San
Carlos (Madrid, Spain), and the Hospital Universitari de Girona Dr.
Josep Trueta (Girona, Spain), respectively, so we certify that all
applicable institutional regulations concerning the ethical use of
information and samples from human volunteers were followed
during this research.
SP-D Gene Polymorphisms
The SP-D gene polymorphism rs721917
(NC_000010.10:g.81706324A.G) was analyzed using iPLEXTM
chemistry on a MALDI-TOF Mass Spectrometer (Sequenom Inc.,
Table 1. Subjects’ characteristics according to the single nucleotide polymorphism rs721917 (NC_000010.10:g.81706324A.G,
Met31Thr) for SP-D gene.
Genotype AA AG GG p{ p* p**
Subjects (M) 468 664 212
Smokers (%) 37 33 36
T2D (%) 14 13 16
Age (years) 51612 52612 53612 0.431 0.275 0.215
BMI (kg/m2) 27.964.3 27.864.3 28.364.5 0.27 0.974 0.238
WHR 0.9560.07 0.9660.08 0.9560.06 0.111 0.158 0.868
Fasting Glucose
(mg/dL)
106.5±35.5 102.1±31.1 104.3±29.8 0.083 0.048 0.438
Glucose 2 h
post-overload (mg/dL)
108.5±39.4 110.8±46.7 121.6±49.4 0.006 0.076 0.003
Fasting Insulin (mU/L) 11.2±9 10.2±6.4 12.2±10.8 0.011 0.353 0.225
Insulin 2 h
post-overload (mU/L)
50.2±55.5 43.3±49.5 66±70.3 0.003 0.894 0.036
HOMAIR 2.74±2.26 2.49±1.69 3.04±3.03 0.008 0.383 0.186
HbA1c (%) 5.361.4 5.261.2 5.361.1 0.363 0.217 0.562
SP-D (ng/mL)# 98.9668.3 92.5667.8 91.5662.4 0.498 0.24 0.336
Subjects (F) 501 641 225
Smokers (%) 17 17 17
T2D (%) 13 10 8
Age (years) 52612 51612 52612 0.478 0.415 0.942
BMI (kg/m2) 29.567.3 28.866.4 2966.2 0.189 0.073 0.339
WHR 0.8460.07 0.8460.07 0.8560.08 0.627 0.542 0.344
Fasting Glucose
(mg/dL)
100.9±37.8 96.6±29.6 93.5±21.4 0.007 0.008 0.001
Glucose 2 h
post-overload (mg/dL)
108.6±38.9 102±31.7 103.7±32.5 0.023 0.011 0.152
Fasting Insulin (mU/L) 11.1612 10.466.4 10.566.3 0.606 0.32 0.593
Insulin 2 h
post-overload (mU/L)
37.2635.2 35.4635.7 32.2642.5 0.67 0.523 0.384
HOMAIR 2.5862.71 2.3861.59 2.3961.56 0.311 0.187 0.374
HbA1c (%) 5.3±1.3 5.1±1.1 4.9±0.7 0.006 0.01 ,0.0001
SP-D (ng/mL)# 95.9±52.8 85.7±51.2 78.6±44.4 0.03 0.015 0.009
T2D: Type 2 diabetes; BMI: Body mass index; WHR: Waist-to-hip ratio; HbA1c: Glycated hemoglobin; HOMAIR: Homeostasis model assessment of insulin resistance;
SP-D: Surfactant protein-D.
#These determinations were performed in a subpopulation of 1,062 subjects.
{for the comparison by ANOVA among the different genotypes;
*for the comparison by test t-student between AA and non-AA individuals, and
**between AA and GG carriers in the whole cohort. Significant differences are shown in bold.
doi:10.1371/journal.pone.0060468.t001
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Table 2. Codominant, dominant, and Log-additive models for SP-D gene polymorphism rs721917
(NC_000010.10:g.81706324A.G, Met31Thr) in the whole cohort after correcting by origin of the sample, age, and sex-effects.
No Type 2 Diabetes Type 2 Diabetes
Model N % N % OR OR CI (95%) P (. |z|)
Codominant
A/A 790 34.8 178 40.5 1 0.009
A/G 1102 48.5 203 46.1 0.82 [0.65/1.04]
G/G 378 16.7 59 13.4 0.6 [0.43/0.84]
Dominant
A/A 790 34.8 178 40.5 1 0.016
A/G-G/G 1480 65.2 262 59.5 0.76 [0.61/0.95]
Log-Additive
(1, 2, 3) 2270 83.8 440 16.2 0.79 [0.67/0.92] 0.002
Fasting Glucose (mg/dL)
Model N Median SE Variation CI (95%) P (. |z|)
Codominant
A/A 967 103.6 1.18 0.001
A/G 1305 99.5 0.84 23.57 [26.1/21.1]
G/G 437 98.9 1.27 25.8 [29.2/22.4]
Dominant
A/A 967 103.6 1.18 ,0.001
A/G-G/G 1742 99.3 0.71 24.13 [26.4/21.8]
Log-Additive
(1, 2, 3) 23.03 24.66 21.41 ,0.001
HbA1c (mg/dL)
Model N Median SE Variation CI (95%) P (. |z|)
Codominant
A/A 537 5.33 0.059 0.003
A/G 710 5.16 0.044 20.15 [20.27/20.03]
G/G 256 5.11 0.058 20.27 [20.44/20.11]
Dominant
A/A 537 5.33 0.058 0.002
A/G-G/G 966 5.15 0.036 20.18 [20.30/20.07]
Log-Additive
(1, 2, 3) 20.14 20.22 20.06 ,0.001
SP-D (ng/mL)
Model N Median SE Variation CI (95%) P (. |z|)
Codominant
A/A 377 96.4 2.95 0.014
A/G 494 88.3 2.45 28.18 [215.3/21.1]
G/G 191 84.6 3.57 212.48 [221.7/23.2]
Dominant
A/A 377 96.4 2.95 0.005
A/G-G/G 685 87.3 2.03 29.38 [216.1/22.7]
Log-Additive
(1, 2, 3) 26.65 211.05 22.06 0.004
OR are odd ratios and OR CI (95%) are their respective 95% confidence interval (CI). P (. |z|) is the P-value of the z-test that tests if the regression coefficients of the
model can be assumed to be zero. Significant differences are shown in bold.
doi:10.1371/journal.pone.0060468.t002
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San Diego, CA, USA), which is a multiple assay format. This SNP
was mixed with other SNPs corresponding to different genes that
are under study in our laboratories. The remaining procedure was
similar to a previously described method for PCR reactions [22].
The products were spotted on a SpectroChip (Sequenom Inc.),
processed and analysed in a Compact Mass Spectrometer by
Mass-ARRAY Workstation (version 3.3) software (Sequenom Inc.).
The high-throughput genotyping assays were performed at the
genotyping facilities of Centro Nacional de Genotipado (CeGen), in the
Node of Santiago.
The intergenic gene polymorphism rs10887344
(NC_000010.10:g.81768162G .A) was genotyped in the subpop-
ulation of subjects recruited at the North-West of Spain (Asturias)
by means of allelic discrimination assays using an ABI Prism 7000
sequence detector and TaqMan technology (Applied Biosystems,
Foster City, CA, USA). The reaction was performed in a final
volume of 25 ml. DNA was amplified after 50 cycles with an initial
denaturation of 10 min at 95uC. The cycle program consisted of
15 sec denaturation at 92uC and 1 min annealing and extension at
60uC. Positive and negative controls, which were correctly
identified, were included in all reactions.
Table 3. Codominant, dominant, and Log-additive models for SP-D gene polymorphism rs721917
(NC_000010.10:g.81706324A.G, Met31Thr) after correcting by origin of the sample, age, sex, and concentrations of SP-D in plasma.
No Type 2 Diabetes Type 2 Diabetes
Model N % N % OR OR CI (95%) P (. |z|)
Codominant
A/A 272 34.1 105 39.6 1 0.039
A/G 373 46.8 121 45.7 0.81 [0.58/1.13]
G/G 152 19.1 39 14.7 0.57 [0.36/0.89]
Dominant
A/A 272 34.1 105 39.6 1 0.051
A/G-G/G 525 65.9 160 60.4 0.73 [0.54/1.00]
Log-Additive
(1, 2, 3) 797 75 265 25 0.76 [0.62/0.94] 0.012
Fasting Glucose (mg/dL)
Model N Median SE Variation CI (95%) P (. |z|)
Codominant
A/A 377 114.9 2.6 0.016
A/G 494 109.4 1.97 25.61 [211.3/0.1]
G/G 191 106.7 2.57 210.42 [217.8/23.0]
Dominant
A/A 377 114.9 2.66 0.011
A/G-G/G 685 108.7 1.59 26.94 [212.3/21.6]
Log-Additive
(1, 2, 3) 25.28 28.88 21.68 0.004
HbA1c (mg/dL)
Model N Median SE Variation CI (95%) P (. |z|)
Codominant
A/A 372 5.38 0.078 0.014
A/G 488 5.22 0.058 20.15 [20.31/0.01]
G/G 189 5.14 0.072 20.302 [20.51/20.09]
Dominant
A/A 372 5.38 0.078 0.012
A/G-G/G 677 5.2 0.047 20.192 [20.34/20.04]
Log-Additive
(1, 2, 3) 20.15 20.25 20.05 0.003
OR are odd ratios and OR CI (95%) are their respective 95% confidence interval (CI). P (. |z|) is the P-value of the z-test that tests if the regression coefficients of the
model can be assumed to be zero. Significant differences are shown in bold.
doi:10.1371/journal.pone.0060468.t003
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Analytical Determinations
Commercially available (BioVendor GmbH, Heidelberg, Ger-
many) solid-phase enzyme-linked immunosorbent assays (ELISA)
based on the sandwich principle were used for the in vitro
quantitative determination of human surfactant protein-D
(n = 1,065) concentrations in plasma. Intra- and inter- assay
coefficients of variation for these determinations were between 5–
10%. Other biochemical measurements were performed as
previously described [6].
Statistical Analyses
The statistical association between the SP-D gene polymor-
phism rs721917 and type 2 diabetes (T2D) was assessed using
custom-written software based on R environment [23]. Depar-
tures from Hardy-Weinberg equilibrium were tested in controls
using a chi-square goodness of fit test with one degree of
freedom. The risk of developing T2D under exposure to this
SP-D SNP was evaluated using logistic regression to estimate
Odd Ratios (OR), considering the AA genotype as the reference
group. Hereby, codominant and dominant (fitting a dominant
model for AA-genotype carriers) models that included the origin
of the samples, age, and sex effects was fitted to estimate the
ORs between the exposure to the GG, AG, and AA genotype.
An additional model (Log-additive) was also fitted under these
conditions. In a second assay of significance, circulating SP-D
concentrations were also included as covariate. Other statistical
analyses and graphics were performed using the program SPSS
(IBM SPSS Statistics, Chicago, IL, USA). One-way ANOVA for
multiple comparisons, using post-hoc by Bonferroni’s test and
the test t-Student when equal variances could be assumed, was
used to compare groups with respect to continuous variables.
In order to replicate the associations found in our population,
we evaluated the SP-D gene polymorphism rs721917
(NC_000010.10: g.81706324A.G) and screened for other
associations within the SP-D genome region in data from
publicly available datasets from the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC). Seven glycemic
traits were evaluated in genome wide association (GWA)
databases of MAGIC, which includes data on continuous
glycaemic traits in a sample of T2D patients and non-diabetic
controls [24,25,26,27,28]. Standard Chi-Squared Tests and
logistic regression tests were used to estimate ORs.
Results
Gene Association Results
The frequency of the G allele in the chromosome 10 at the
position rs721917 NC_000010.10: g.81706324A.G (Contig
position) of the surfactant protein-D (SP-D) gene was lower in subjects
with impaired glucose tolerance and T2D (IGT, Table 1). Indeed,
the increased prevalence of the A allele run in parallel to increased
circulating SP-D concentrations (Table 1), fasting glucose, and
glycated hemoglobin in women, but not in men (Figure 1a and
1b).
The study had a power .75% for estimating ORs .1.7 with a
MAFs .0.70 and a=0.05. The similar ORs for the AG and GG
genotypes obtained for the codominant model suggest the
possibility of fitting a dominant model for AA-genotype carriers
(Table 2). In this case, the residual deviance of the genotype, once
origin, age, and gender were added to the model, reached a p-
value ,0.001. An additional model (Log-additive) that included
origin, age, and gender effects was also fitted. GG homozygotes
had 40% (p= 0.0025) lower prevalence of T2D than A-allele
carriers, estimated by the Log-additive model (Table 2). In
agreement, significantly decreased fasting glucose (p = 0.0003) and
glycated hemoglobin (p = 0.0006) was found in the whole cohort of
G allele carriers (Table 2). No significant differences between
genotypes were found for fasting insulin in this population. Similar
results were found in additional models that included the effect of
BMI or other anthropometrical parameters. Some T2D partici-
pants were under treatment (fibrates, statins, oral hypoglycemic
drugs, and/or insulin). However, it should be noted that the main
Figure 2. Regional association plot of chr.10. Regional association plot of the chromosome 10 region for fasting insulin and HOMA-IR in MAGIC
GWA.
doi:10.1371/journal.pone.0060468.g002
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findings remained essentially unchanged after the exclusion of
these subjects (data not shown).
Circulating SP-D Concentrations
To further study the possible biological significance of this
association we hypothesized a link among the SP-D gene
polymorphism rs721917, circulating SP-D concentrations, and
risk factors for T2D. In this sample of subjects (n = 1,062), G-allele
carriers had decreased circulating SP-D than AA-subjects (p-
additive = 0.0042, Table 1). Currently, the increased frequency of
the A allele run in parallel to increased sex-adjusted SP-D
concentrations (Fig. 1c), fasting glucose (p-additive = 0.004, Fig. 1d),
and glycated hemoglobin (p-additive = 0.0035, Fig. 1e), especially
among women. Of note, the significance of differences in fasting
glucose between groups after controlling for origin, age, and
gender remained significant when correcting for SP-D concentra-
tions in plasma (Table 3).
On the other hand, circulating SP-D concentrations were
significantly decreased in T2D when compared to non-diabetic
subjects in both non-obese and obese individuals, and inversely
associated with BMI, fat mass, fasting glucose, and fasting
triglycerides, as previously reported [19], and independently of
genetic variations.
Validation of the Association through Screening of
MAGIC GWA Databases
In order to validate the association between SP-D gene variants
and T2D we explored the data generated in genome wide
association (GWA) databases from the Meta-Analyses of Glucose
and Insulin-related traits Consortium (MAGIC), who measures
Figure 3. Genotypes for rs10887344 and measures of impaired glucose tolerance. Mean and 95% confidence interval for fasting glucose
(Fig. 3a), fasting insulin (Fig. 3b), HOMA-IR (Fig. 3c), and glycated hemoglobin (Fig. 3d) according to the genotypes for rs10887344. Men: black bars,
women: grey bars. *p,0.05 for comparisons with GG-genotype.
doi:10.1371/journal.pone.0060468.g003
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continuous glycaemic traits [24]. In this larger cohort, fasting
Insulin (p = 0.0009) and HOMAIR (p = 0.0017) were associated to
rs721917 SP-D SNP following the additive model (Figure 2).
Contrary to what might be expected, no significant changes
regarding glucose concentrations were found.
In addition to the association of the SP-D gene polymorphism
rs721917, a second SNP (rs10887344; chr10:81768162), located
between SP-D gene and LOC219347, 59.3 Kb upstream of the SP-
D gene (but not in LD with the first polymorphism analyzed, the
rs721917, r2 = 0.082), was also associated with fasting insulin
(p = 0.000078; Figure 2) and HOMAIR in this GWA. Of note,
associations of this intergenic SNP (rs10887344) with parameters
of insulin resistance were replicated in our sample (Table 4).
Indeed, in agreement with results from MAGIC GWA, increased
fasting glucose (p = 0.04; Fig. 3a), fasting insulin (Fig. 3b),
HOMAIR (p= 0.022; Fig. 3c), and glycated hemoglobin
(p = 0.015; Fig. 3d) was found in GG carriers for rs10887344
when compared to AA genotype (Table 4), independently of sex,
BMI, and circulating SP-D. Then, according to results for this
second SNP associated with SP-D gene (rs10887344), GG
homozygotes had higher prevalence of T2D than A-allele carriers.
Discussion
Polymorphisms of common receptors in the innate immune
system like mannose-binding lectin [29], and toll-like receptors
[30] are associated with altered susceptibility to infection, and the
risk of a variety of inflammatory diseases. Indeed, many genetic
variants in the innate immune factors are associated with several
metabolic risk factors for T2D, an observation that provides a
rationale for further studying their role as biomarkers for the early
risk prediction of this disease [31,32].
Genetic variations in the coding region of surfactant protein-D (SP-
D) are associated with an increased risk of T2D (current report).
Surfactant collectins such as SP-D are well known to be involved
in lung innate immunity, being a key factor in the prevention of
respiratory infections (see [33] for a review). In a scenario of
repeated injuries and exposure to infectious agents, a chronic
inflammatory response has been proposed as a leading factor for
the development of metabolic disturbances and insulin resistance
[34]. Lipopolysaccharides (LPS), for example, are at the onset of
high-fat diet-induced metabolic diseases by triggering low grade
chronic inflammation [35].
Surfactant immune function is primarily attributed to SP-A and
-D. These proteins opsonize pathogens, regulate the inflammatory
response, and interact with the adaptive immune response, being
involved in the susceptibility to inflammation and infection [36].
In a previous manuscript, we found cross-sectional and longitu-
dinal associations of circulating SP-D concentrations with insulin
resistance and T2D [19]. In this study, we describe that the
31 MetRThr SP-D gene single nucleotide polymorphism (SNP)
rs721917 was associated with insulin resistance and the prevalence
of T2D. Interestingly, differences in fasting glucose between
groups after controlling for origin, age, and gender remained
significant when controlling for SP-D concentrations in plasma.
This suggests that the possible influence of the SNP rs721917 on
metabolism may arise from changes in the molecular structure
and/or functional properties of SP-D protein rather than through
changes in its circulating concentrations. Indeed, this non-
synonymous polymorphic variation of the N-terminal domain of
the SP-D affects oligomerization and function, as well as
circulating concentrations [10,11], changes that may explain the
relationship with insulin resistance and T2D. In fact, subjects
carrying the AA genotype (Met/Met) showed increased circulating
SP-D concentrations in parallel to increased fasting glucose and
T2D prevalence, especially among women and independently of
circulating SP-D.
The putative functional consequences of rs721917 were
explored using the FastSNP SNP characterization online applica-
tion (http://fastsnp.ibms.sinica. edu.tw/). The SNP rs721917
involves a missense variation leading to conservative changes that
appeared not only to affect the amino acid sequence of the protein
but also to cause a disruption of three Exonic Splicing Enhancer
(ESE) sequences, according to the systematic analysis of ESE
sequences by Fairbrother et al. [37]. As three ESE are disrupted by
this SNP (Figure S1), it is very likely that this SNP has an effect on
alternative splicing, altering stability and circulating concentra-
tions and even affecting biological functions. Accordingly, Leth-
Larsen et al. [11] demonstrated that GG-carriers (Thr/Thr)
produce almost exclusively monomers of SP-D, whereas subjects
carrying AA genotype show multimers such as dodecamers and
trimers of subunits. These high weight polimers of SP-D may bind
to viruses and both Gram-positive and negative bacteria, while the
monomeric species seem to bind LPS almost exclusively [11].
Thereby, the different genotypes may predispose individuals to
different buffering capacity of metabolic endotoxemia. Indeed, the
codons corresponding to this amino acid residue in the mature
protein, here found to be linked to T2D, were associated with
increase susceptibility to immune-related diseases [38,39]. Inter-
estingly, in a subpopulation of 71 subjects (25 AA, 31 AG, and
15 GG-subjects), we observed an inverse association between free
LPS concentrations in plasma and circulating SP-D in GG
Table 4. Subjects’ characteristics according to the intergenic
single nucleotide polymorphism rs10887344
(NC_000010.10:g.81768162G .A).
Genotype GG GA AA p* p{
Subjects
(M/F)
65/82 135/145 84/112
Smokers (%) 20 29 24
T2D (%) 14 8 8
Age (years) 52613 53612 51613 0.139 0.251
BMI (kg/m2) 28.264.7 28.264.8 27.664.5 0.295 0.227
WHR 0.8860.07 0.8960.09 0.8760.09 0.054 0.382
Fasting
Glucose
(mg/dL)
102.9±36.8 98.3±21.3 96.5±20.8 0.065 0.041
Glucose
2 h-post
overload
(mg/dL)
117.1656.7 116.8650.3 108.4643.2 0.166 0.128
Fasting
insulin
(mUI/dL)
9.1±7 9.8±8.4 8.1±4.8 0.039 0.118
HOMAIR 2.5±2.5 2.5±2.7 2.1±1.4 0.026 0.022
HbA1c (%) 5.0±1.1 4.8±0.8 4.7±0.7 0.026 0.015
SP-D
(ng/mL)
97.2653.6 103.8663.8 98.3655.5 0.524 0.864
T2D: Type 2 diabetes; BMI: Body mass index; WHR: Waist-to-hip ratio; HbA1c:
Glycated hemoglobin; SP-D: Surfactant protein-D; MBL: Mannose binding
lectin.
*for the comparison by ANOVA among the different genotypes, and
{for the comparison by test t-student between AA and GG carriers in the whole
cohort. Significant differences are shown in bold.
doi:10.1371/journal.pone.0060468.t004
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subjects (r =20.50, p= 0.05), but not among A allele carriers (data
not shown).
On the other hand, our results indicated that gender may
influence the degree of susceptibility to T2D of subjects who share
the AA genotype. It is becoming increasingly recognized that there
are gender differences in pulmonary disease susceptibility and
severity, being women apparently more sensitive to pulmonary
injury than men [40,41]. Indeed, there are well-known gender-
related differences in the composition of surfactant lipids and
lipoproteins such as the surfactant protein B and C [42,43]. Our
results indicate that the presence of the variant SP-D allele (Met/
Met) increases the odds of developing insulin resistance and T2D
preferentially among women.
The analyses of SP-D variants in GWAS datasets from MAGIC
reinforce the association with T2D. In these datasets, the
associations of insulin resistance with this SNP, but also with
different SNPs other than those genotyped for this study, suggest
that the influence of rs721917 variant might be capturing the
association of other variants, such as rs10887344. Concurrently,
the effects of this variant on circulating SP-D and insulin sensitivity
were tested in a subpopulation of this study confirming the
association with the prevalence of T2D in both men and women,
although not changing plasma SP-D concentrations. Then, the
rs10887344 turns to be a promising variant to test in further large
scale association studies. Unfortunately, we were not able to test
this SNP in other large published case-control data, as this SNP
was not directly typed by any of these studies and genotype data at
the individual level was not available in order to impute it from the
datasets.
Overall, the findings reported here suggest the implication of
SP-D variants in the modulation of metabolic parameters. The SP-
D gene polymorphism rs721917, beyond modifying circulating
concentrations, may modify SP-D structure, changing its specific-
ity against infectious agents and other external agents [11].
Triggering factors such as weight gain, aging, and repeated usual-
life infections, among others, results in low-grade chronic
inflammation which would be amplified in A-allele carriers. In
the long term this process worsens insulin resistance, leading to
T2D. However, the mechanisms responsible for the different
associations should be investigated further.
Supporting Information
Figure S1 Functional aspects of rs721917. Functional
aspects of rs721917 according to the FastSNP SNP characteriza-
tion online application (http://fastsnp.ibms.sinica. edu.tw/).
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